je.st
news
Home
› Baxter BioScience Announces Positive Phase III Results For BAX 817, Investigational Recombinant Treatment For Hemophilia A And B Patients With Inhibitors
Baxter BioScience Announces Positive Phase III Results For BAX 817, Investigational Recombinant Treatment For Hemophilia A And B Patients With Inhibitors
2015-04-01 07:33:48| drugdiscoveryonline Home Page
Baxter International Inc. recently announced positive results from its Phase III clinical trial evaluating the safety and efficacy of BAX 817, an investigational recombinant factor VIIa (rFVIIa) treatment for people with hemophilia A or B who develop inhibitors
Tags: with
results
iii
positive
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||